Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Neoplasms 7Melanoma 5Squamous Cell Carcinoma of Head and Neck 4Head and Neck Neoplasms 4Triple Negative Breast Neoplasms 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Solid Tumor, Adult 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Bites and Stings 2Turcot syndrome 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Oligoprogressive 1Multiple Myeloma 1Liver Neoplasms 1Kidney Neoplasms 1Histiocytoma, Malignant Fibrous 1First-line Advanced NSCLC Patients 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Dermatofibrosarcoma 1Colonic Neoplasms 1

Interventions

pembrolizumab 14Nivolumab 13Sunitinib 12Axitinib 9cabozantinib 8belzutifan 8Ipilimumab 7Everolimus 5atezolizumab 4Sorafenib 4temsirolimus 3perifosine 3motexafin gadolinium 3Drug Therapy 3spartalizumab 2palbociclib 2liposomal doxorubicin 2lenvatinib 2entinostat 2ciforadenant 2belinostat 2avelumab 2Paclitaxel 2Immunotherapy 2G250 monoclonal antibody 2Fluorouracil 2Docetaxel 2Dexamethasone 2Cetuximab 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Kidney Neoplasms × Immune Checkpoint Inhibitors × Clear all
NCT05704985 2025-05-29

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

DEKA Biosciences

Phase 1 Active not recruiting
39 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Neoplasms, Pancreatic Neoplasms, Skin Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡